MiR-34a inhibitor protects mesenchymal stem cells from hyperglycaemic injury through the activation of the SIRT1/FoxO3a autophagy pathway

Abstract Background Mesenchymal stem cells (MSCs) are favourable treatments for ischaemic diseases; however, MSCs from diabetic patients are not useful for this purpose. Recent studies have shown that the expression of miR-34a is significantly increased in patients with hyperglycaemia; the precise r...

Full description

Bibliographic Details
Main Authors: Fengyun Zhang, Fei Gao, Kun Wang, Xiaohong Liu, Zhuoqi Zhang
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Stem Cell Research & Therapy
Subjects:
Online Access:https://doi.org/10.1186/s13287-021-02183-2
id doaj-c589eb85d7f6420aab79a2bce1ffa24b
record_format Article
spelling doaj-c589eb85d7f6420aab79a2bce1ffa24b2021-02-07T12:09:57ZengBMCStem Cell Research & Therapy1757-65122021-02-0112111410.1186/s13287-021-02183-2MiR-34a inhibitor protects mesenchymal stem cells from hyperglycaemic injury through the activation of the SIRT1/FoxO3a autophagy pathwayFengyun Zhang0Fei Gao1Kun Wang2Xiaohong Liu3Zhuoqi Zhang4Department of Cardiology, the Affiliated Hospital of Xuzhou Medical UniversityDepartment of Cardiology, Institute of Cardiovascular Research, Affiliated Hospital of Xuzhou Medical UniversityDepartment of Cardiology, First People’s Hospital of SuqianDepartment of Cardiology, Institute of Cardiovascular Research, Affiliated Hospital of Xuzhou Medical UniversityDepartment of Cardiology, the Affiliated Hospital of Xuzhou Medical UniversityAbstract Background Mesenchymal stem cells (MSCs) are favourable treatments for ischaemic diseases; however, MSCs from diabetic patients are not useful for this purpose. Recent studies have shown that the expression of miR-34a is significantly increased in patients with hyperglycaemia; the precise role of miR-34a in MSCs in diabetes needs to be clarified. Objective The aim of this study is to determine the precise role of miR-34a in MSCs exposed to hyperglycaemia and in recovery heart function after myocardial infarction (MI) in diabetes mellitus (DM) rats. Methods DM rat models were established by high-fat diet combined with streptozotocin (STZ) injection. MSCs were isolated from the bone marrow of donor rats. Chronic culture of MSCs under high glucose was used to mimic the DM micro-environment. The role of miR-34a in regulating cell viability, senescence and paracrine effects were investigated using a cell counting kit-8 (CCK-8) assay, senescence-associated β-galactosidase (SA-β-gal) staining and vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) ELISA, respectively. The expression of autophagy- and senescence-associated proteins in MSCs and silent information regulator 1 (SIRT1) and forkhead box class O 3a (FoxO3a) were analysed by western blotting. Autophagic bodies were analysed by transmission electron microscopy (TEM). The MI model was established by left anterior descending coronary artery (LAD) ligation, and then, the rats were transplanted with differentially treated MSCs intramuscularly at sites around the border zone of the infarcted heart. Thereafter, cardiac function in rats in each group was detected via cardiac ultrasonography at 1 week and 3 weeks after surgery. The infarct size was determined through a 2,3,5-triphenyltetrazolium chloride (TTC) staining assay, while myocardial fibrosis was assessed by Masson staining. Results The results of the current study showed that miR-34a was significantly increased under chronic hyperglycaemia exposure. Overexpression of miR-34a was significantly associated with impaired cell viability, exacerbated senescence and disrupted cell paracrine capacity. Moreover, we found that the mechanism underlying miR-34a-mediated deterioration of MSCs exposed to high glucose involved the activation of the SIRT1/FoxO3a autophagy pathway. Further analysis showed that miR-34a inhibitor-treated MSC transplantation could improve cardiac function and decrease the scar area in DM rats. Conclusions Our study demonstrates for the first time that miR-34a mediates the deterioration of MSCs’ functions under hyperglycaemia. The underlying mechanism may involve the SIRT1/FoxO3a autophagy signalling pathway. Thus, inhibition of miR-34a might have important therapeutic implications in MSC-based therapies for myocardial infarction in DM patients.https://doi.org/10.1186/s13287-021-02183-2Microrna-34aMesenchymal stem cellsHyperglycaemiaSenescenceAutophagy
collection DOAJ
language English
format Article
sources DOAJ
author Fengyun Zhang
Fei Gao
Kun Wang
Xiaohong Liu
Zhuoqi Zhang
spellingShingle Fengyun Zhang
Fei Gao
Kun Wang
Xiaohong Liu
Zhuoqi Zhang
MiR-34a inhibitor protects mesenchymal stem cells from hyperglycaemic injury through the activation of the SIRT1/FoxO3a autophagy pathway
Stem Cell Research & Therapy
Microrna-34a
Mesenchymal stem cells
Hyperglycaemia
Senescence
Autophagy
author_facet Fengyun Zhang
Fei Gao
Kun Wang
Xiaohong Liu
Zhuoqi Zhang
author_sort Fengyun Zhang
title MiR-34a inhibitor protects mesenchymal stem cells from hyperglycaemic injury through the activation of the SIRT1/FoxO3a autophagy pathway
title_short MiR-34a inhibitor protects mesenchymal stem cells from hyperglycaemic injury through the activation of the SIRT1/FoxO3a autophagy pathway
title_full MiR-34a inhibitor protects mesenchymal stem cells from hyperglycaemic injury through the activation of the SIRT1/FoxO3a autophagy pathway
title_fullStr MiR-34a inhibitor protects mesenchymal stem cells from hyperglycaemic injury through the activation of the SIRT1/FoxO3a autophagy pathway
title_full_unstemmed MiR-34a inhibitor protects mesenchymal stem cells from hyperglycaemic injury through the activation of the SIRT1/FoxO3a autophagy pathway
title_sort mir-34a inhibitor protects mesenchymal stem cells from hyperglycaemic injury through the activation of the sirt1/foxo3a autophagy pathway
publisher BMC
series Stem Cell Research & Therapy
issn 1757-6512
publishDate 2021-02-01
description Abstract Background Mesenchymal stem cells (MSCs) are favourable treatments for ischaemic diseases; however, MSCs from diabetic patients are not useful for this purpose. Recent studies have shown that the expression of miR-34a is significantly increased in patients with hyperglycaemia; the precise role of miR-34a in MSCs in diabetes needs to be clarified. Objective The aim of this study is to determine the precise role of miR-34a in MSCs exposed to hyperglycaemia and in recovery heart function after myocardial infarction (MI) in diabetes mellitus (DM) rats. Methods DM rat models were established by high-fat diet combined with streptozotocin (STZ) injection. MSCs were isolated from the bone marrow of donor rats. Chronic culture of MSCs under high glucose was used to mimic the DM micro-environment. The role of miR-34a in regulating cell viability, senescence and paracrine effects were investigated using a cell counting kit-8 (CCK-8) assay, senescence-associated β-galactosidase (SA-β-gal) staining and vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) ELISA, respectively. The expression of autophagy- and senescence-associated proteins in MSCs and silent information regulator 1 (SIRT1) and forkhead box class O 3a (FoxO3a) were analysed by western blotting. Autophagic bodies were analysed by transmission electron microscopy (TEM). The MI model was established by left anterior descending coronary artery (LAD) ligation, and then, the rats were transplanted with differentially treated MSCs intramuscularly at sites around the border zone of the infarcted heart. Thereafter, cardiac function in rats in each group was detected via cardiac ultrasonography at 1 week and 3 weeks after surgery. The infarct size was determined through a 2,3,5-triphenyltetrazolium chloride (TTC) staining assay, while myocardial fibrosis was assessed by Masson staining. Results The results of the current study showed that miR-34a was significantly increased under chronic hyperglycaemia exposure. Overexpression of miR-34a was significantly associated with impaired cell viability, exacerbated senescence and disrupted cell paracrine capacity. Moreover, we found that the mechanism underlying miR-34a-mediated deterioration of MSCs exposed to high glucose involved the activation of the SIRT1/FoxO3a autophagy pathway. Further analysis showed that miR-34a inhibitor-treated MSC transplantation could improve cardiac function and decrease the scar area in DM rats. Conclusions Our study demonstrates for the first time that miR-34a mediates the deterioration of MSCs’ functions under hyperglycaemia. The underlying mechanism may involve the SIRT1/FoxO3a autophagy signalling pathway. Thus, inhibition of miR-34a might have important therapeutic implications in MSC-based therapies for myocardial infarction in DM patients.
topic Microrna-34a
Mesenchymal stem cells
Hyperglycaemia
Senescence
Autophagy
url https://doi.org/10.1186/s13287-021-02183-2
work_keys_str_mv AT fengyunzhang mir34ainhibitorprotectsmesenchymalstemcellsfromhyperglycaemicinjurythroughtheactivationofthesirt1foxo3aautophagypathway
AT feigao mir34ainhibitorprotectsmesenchymalstemcellsfromhyperglycaemicinjurythroughtheactivationofthesirt1foxo3aautophagypathway
AT kunwang mir34ainhibitorprotectsmesenchymalstemcellsfromhyperglycaemicinjurythroughtheactivationofthesirt1foxo3aautophagypathway
AT xiaohongliu mir34ainhibitorprotectsmesenchymalstemcellsfromhyperglycaemicinjurythroughtheactivationofthesirt1foxo3aautophagypathway
AT zhuoqizhang mir34ainhibitorprotectsmesenchymalstemcellsfromhyperglycaemicinjurythroughtheactivationofthesirt1foxo3aautophagypathway
_version_ 1724281609155248128